A number of firms have modified their ratings and price targets on shares of Novavax (NASDAQ: NVAX) recently:

  • 8/19/2017 – Novavax was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women’s health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants. “
  • 8/16/2017 – Novavax was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $1.25 price target on the stock. According to Zacks, “NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women’s health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants. “
  • 8/14/2017 – Novavax was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 8/9/2017 – Novavax was upgraded by analysts at Ladenburg Thalmann Financial Services from a “neutral” rating to a “buy” rating. They now have a $1.60 price target on the stock.
  • 8/5/2017 – Novavax was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/27/2017 – Novavax had its “neutral” rating reaffirmed by analysts at Chardan Capital. They now have a $1.50 price target on the stock.
  • 7/27/2017 – Novavax was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 7/26/2017 – Novavax had its “hold” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $1.50 price target on the stock.
  • 7/26/2017 – Novavax was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women’s health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants. “
  • 7/21/2017 – Novavax had its “hold” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $2.00 price target on the stock. They wrote, “Important RSV vaccine data to be released next Monday. NVAX plans to host a conference call on Monday, July 24, at 4:30pm EDT, on which top-line data from the E-205 Phase 2 clinical trial of the RSV vaccine candidate in older adults will be discussed. The company’s press release notes that an update of the ongoing pivotal Prepare trial of the vaccine candidate in pregnant women will also be provided. Of the two programs, we believe the former is likely to be the greater value creator and, if the data are encouraging, could provide a catalyst for renewed investor interest in the stock.””
  • 7/19/2017 – Novavax was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.

Shares of Novavax, Inc. (NASDAQ NVAX) opened at 1.00 on Tuesday. The stock’s market cap is $289.90 million. Novavax, Inc. has a 1-year low of $0.73 and a 1-year high of $8.49. The company’s 50-day moving average is $1.12 and its 200 day moving average is $1.13.

Novavax (NASDAQ:NVAX) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.16). The company had revenue of $6.70 million during the quarter, compared to the consensus estimate of $6.15 million. Novavax had a negative net margin of 1,006.00% and a negative return on equity of 787.38%. The company’s revenue for the quarter was up 168.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.29) earnings per share. Equities research analysts anticipate that Novavax, Inc. will post ($0.62) EPS for the current year.

Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.

Receive News & Stock Ratings for Novavax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc and related stocks with our FREE daily email newsletter.